Friday, July 28, 2017 11:06:43 AM
"EnteroMedics is now working, Galvani, is the brainchild of GlaxoSmithKline and Verily Life Sciences (an Alphabet company) that was established in 2016 to enable the research, development, and commercialization of bioelectronic medicines.
In other words, EnteroMedics is now one-third of a three company setup, which is in place to develop a technology that EnteroMedics is going to retain the exclusive rights to the US, with the other two-thirds of the team being Google, arguably the most influential technology company in the world and GlaxoSmithKline, arguably holding the same title in the pharmaceutical space and definitely as relates to health and wellness (and importantly, weight loss).
This completely changes the nature of an EnteroMedics exposure.
No longer does the company need major coverage from insurers to justify the existence of its technology. If Google and GSK can successfully apply the technology to a new product, one that these two behemoths then set out to commercialize in the US, EnteroMedics doesn’t really need to worry about driving sales on its own of the initial iteration of the product, vBloc, in order to generate revenues."
https://insiderfinancial.com/enteromedics-inc-nasdaqetrm-just-made-a-game-changing-announcement-and-markets-missed-it
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM